Foreign media: China's biotechnology industry is developing at a lower cost and faster speed, challenging the US's dominant position.
China has established biotechnology centers in places such as Wuxi, attracting global pharmaceutical companies to research and produce drugs here. Despite challenges such as US tariffs, China's biotechnology industry is still thriving, with its stocks rising more than 60% since the beginning of the year.
China's advantages include shortening the clinical trial period (two to three times faster than the US), lower costs by about 30%, and completing drug development and market launch within 16 months, launching cheaper generic drugs and new drugs, such as the cancer mRNA vaccine developed by Licon Life Sciences, which costs about $21,000. By accelerating drug testing and production, China provides cheaper medicines, including generic drugs, meeting global demand. Companies such as WuXi AppTec in Wuxi provide one-stop R&D and production services for domestic and international pharmaceutical companies, participating in the development of many drugs used in the US.
China is promoting the development of the biotechnology industry through supporting R&D, cultivating talents, and reforming the drug approval process. Although China still has a gap in frontier science, its progress is significant, and it has also begun to make breakthroughs in innovative fields such as mRNA vaccines. The US needs to re-examine the development of China's biotechnology industry, considering its advantages in reducing costs and improving accessibility, rather than merely viewing it as a threat.
Original: www.toutiao.com/article/1840685154832391/
Statement: This article represents the views of the author.